TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Breast Cancer
Interventions: DRUG: docetaxel|DRUG: doxorubicin or epirubicin|DRUG: cyclophosphamide|DRUG: gemcitabine|DRUG: cisplatin
Sponsor: Fudan University